Aerie pharmaceuticals announces positive phase 3 topline results for netarsudil ophthalmic solution 0.02% clinical trial in japan

Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq:aeri), an ophthalmic pharmaceutical company, today reported positive topline results for the company's phase 3 clinical trial in japan evaluating netarsudil ophthalmic solution 0.02% (“netarsudil 0.02%”) versus ripasudil hydrochloride hydrate ophthalmic solution 0.4% (“ripasudil 0.4%”). the results showed that netarsudil 0.02% once daily was superior to ripasudil 0.4% twice daily in lowering intraocular pressure (“iop”) at week
AERI Ratings Summary
AERI Quant Ranking